TriLipix combo boosts HDL 21%

US health care major Abbott says that, in 276 type 2 diabetes patients included in the sub-group analysis of a recent trial, TriLipix 135mg plus rosuvastatin 10mg yielded an increase in high-density lipoprotein of 21% and decrease in triglycerides of 44.7% compared to an HDL increase of 6.6% and triglyceride decrease of 28.8% with rosuvastatin 10mg alone. LDL decreased 37.1% with the combination compared to 6.1% with TriLipix 135mg monotherapy.

Patients treated with the combination of TriLipix 135mg and rosuvastatin 20mg had an increase in HDL of 17.6% and decrease in triglycerides of 42.4% compared to an HDL rise of 12.2% and triglyceride fall of 26.8% with rosuvastatin 20mg alone. LDL decreased 37.4% with the combination compared to 6.1% with TriLipix 135mg monotherapy.

"New treatment options are critical given that a substantial number of patients are not achieving treatment goals for their three key lipids," said Eugene Sun, vice president, global pharmaceutical clinical development at Abbott. "Abbott has built a robust clinical program to support TriLipix to provide physicians and patients with as much data as possible to help them evaluate this potential new therapy," he added.